lasmiditan Reyvow
Selected indexed studies
- Lasmiditan (Reyvow) for the Treatment of Acute Migraine. (Am Fam Physician, 2020) [PMID:33320510]
- Migraine. (Nat Rev Dis Primers, 2022) [PMID:35027572]
- Diagnosis and Management of Headache: A Review. (JAMA, 2021) [PMID:33974014]
_Worker-drafted node — pending editorial review._
Connections
lasmiditan Reyvow is a side effect of
Sources
- Migraine overview and summary of current and emerging treatment options. (2019) pubmed
- Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. (2021) pubmed
- Lasmiditan: First Approval. (2019) pubmed
- Lasmiditan (Reyvow) for the Treatment of Acute Migraine. (2020) pubmed
- Migraine. (2022) pubmed
- Diagnosis and Management of Headache: A Review. (2021) pubmed
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. (2021) pubmed
- Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. (2021) pubmed
- Acute Treatment of Migraine. (2024) pubmed
- An update on pharmacotherapy for trigeminal neuralgia. (2024) pubmed